|
|
|
13.04.26 - 16:06
|
Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce Pendency of Class Action Involving Purchasers of Natera, Inc. Common Stock (PR Newswire)
|
|
|
RADNOR, Pa., April 13, 2026 /PRNewswire/ -- UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS BRITISH AIRWAYS PENSION TRUSTEES LIMITED & KEY WEST POLICE AND FIRE PENSION FUND, Individually and on Behalf of All Others Similarly Situated, Plaintiffs, v. NATERA, INC., et al., Defendants.......
|
|
|
|
|
|
|
|
|
27.03.26 - 13:06
|
CHMP empfiehlt Roche-Kombi mit Zepzelca bei Lungenkrebs (Cash)
|
|
|
- Der Ausschuss für Humanarzneimittel (CHMP) der European Medicines Agency hat eine positive Stellungnahme für den Wirkstoff Zepzelca von PharmaMar in Kombination mit Atezolizumab von Roche abgegeben. Empfohlen wird der Einsatz als Erstlinien-Erhaltungstherapie bei erwachsenen Patienten mit fortgeschrittenem kleinzelligem Lungenkrebs im extensiven Stadium....
|
|
|
25.03.26 - 14:55
|
Grifols Aims to Raise Up to $5 Billion in IPO of US Unit (Bloomberg)
|
|
|
Grifols SA aims to raise as much as $5 billion in a potential US listing of its Los Angeles-based biopharma unit, an amount that would value the business at close to four times the size of its parent company, according to a person familiar with the matter....
|
|
|
25.03.26 - 13:03
|
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance (GlobeNewswire EN)
|
|
|
MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US 17/439,575, entitled “Methods of treating borderline personality disorder”, further strengthening its intellectual property portfolio for vafidemstat, Oryzon's LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, including borderline personality disorder (BPD). The allowed claims cover the use of LSD1 inhibitors for the treatment of non-aggressive symptoms of BPD, complementing Oryzon's patent portfolio in aggression....
|
|
|
|
|
|
|
|
|
23.03.26 - 13:03
|
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent US12,564,559 B2, relating to therapeutic combinations of iadademstat, Oryzon's potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
